Storia in 10 fonti

Evidence vs influencers: The FDA vote putting patients in danger

Patient demand and influencer hype cannot replace clinical testing: the FDA must stop legitimizing unapproved compounded peptides.

Raccontata da

washingtonexaminer.com

endpoints.news

zerohedge.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

washingtonexaminer.comStai leggendo2 g fa

Evidence vs influencers: The FDA vote putting patients in danger

Patient demand and influencer hype cannot replace clinical testing: the FDA must stop legitimizing unapproved compounded peptides.

originale

Timeline cronologica

venerdì 24 luglio 2026·medpagetoday.com
FDA Panel Finds a Peptide It Doesn't Like
Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list
venerdì 24 luglio 2026·statnews.com
FDA advisory panel narrowly rejects compounding of one peptide, backs another
Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.

abcnews.com

5 g fa

FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

An advisory committee for the Food and Drug Administration has narrowly voted to add six peptides to a drug compounding list.

Leggi questa versione → originale

gizmodo.com5 g fa

FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do

This week, the FDA's Pharmacy Compounding Advisory Committee largely voted yes to allowing several peptides be produced by compounding pharmacies.

Leggi questa versione → originale

endpoints.news2 g fa

Six wellness peptides win backing from FDA advisory committee, setting up future agency action

FDA advisory panel voted to lift restrictions on peptides BPC-157, TB-500, KPV, MOTS-c, epitalon & semax, backed by RFK Jr., despite FDA staff safety concerns.

Leggi questa versione → originale

medpagetoday.com5 g fa

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Leggi questa versione → originale

zerohedge.com8 h fa

FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns

Peptides are short chains of amino acids that help regulate metabolism, growth and tissue repair...

Leggi questa versione → originale

venerdì 24 luglio 2026·

statnews.com

FDA advisory panel narrowly rejects compounding of one peptide, back another

Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.

venerdì 24 luglio 2026·

fortune.com

RFK Jr.'s peptide push narrowly gains backing from FDA advisers despite objections from scientists | Fortune

The panel voted 8-6 despite agency scientists’ warnings that certain peptide chemicals lack evidence of safety or effectiveness.

venerdì 24 luglio 2026·

gizmodo.com

FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do

This week, the FDA's Pharmacy Compounding Advisory Committee largely voted yes to allowing several peptides be produced by compounding pharmacies.

venerdì 24 luglio 2026·

nbcnews.com

‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugs

An FDA panel with ties to the industry recommended loosening regulations on six peptides over objections from FDA scientists over a lack of data.

venerdì 24 luglio 2026·

france24.com

US panel endorses more unproven if buzzy peptides

A US review panel on Friday recommended loosening restrictions on all but one of a buzzy class of peptides, dismissing protests from medical experts who say none are well-studied…

sabato 25 luglio 2026·

abcnews.com

FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

An advisory committee for the Food and Drug Administration has narrowly voted to add six peptides to a drug compounding list.

lunedì 27 luglio 2026·

washingtonexaminer.com

Evidence vs influencers: The FDA vote putting patients in danger

Patient demand and influencer hype cannot replace clinical testing: the FDA must stop legitimizing unapproved compounded peptides.

lunedì 27 luglio 2026·

endpoints.news

Six wellness peptides win backing from FDA advisory committee, setting up future agency action

FDA advisory panel voted to lift restrictions on peptides BPC-157, TB-500, KPV, MOTS-c, epitalon & semax, backed by RFK Jr., despite FDA staff safety concerns.

martedì 28 luglio 2026·

endpoints.news

The future of gray-market peptides

FDA advisory panel voted to allow compounding pharmacies to make 6 of 7 peptides, despite safety/efficacy concerns, with Revelation Pharma's Shawn Hodges cautiously optimistic.

mercoledì 29 luglio 2026·

zerohedge.com

FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns

Peptides are short chains of amino acids that help regulate metabolism, growth and tissue repair...

Evidence vs influencers: The FDA vote putting patients in danger

Timeline cronologica

FDA Panel Finds a Peptide It Doesn't Like

FDA advisory panel narrowly rejects compounding of one peptide, backs another

FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do

Six wellness peptides win backing from FDA advisory committee, setting up future agency action

FDA Panel Finds a Peptide It Doesn't Like

FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns

FDA advisory panel narrowly rejects compounding of one peptide, back another

RFK Jr.'s peptide push narrowly gains backing from FDA advisers despite objections from scientists | Fortune

FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do

‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugs

US panel endorses more unproven if buzzy peptides

FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

Evidence vs influencers: The FDA vote putting patients in danger

Six wellness peptides win backing from FDA advisory committee, setting up future agency action

The future of gray-market peptides

FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns